PCSK9 inhibitors from bench to real world: a journey to improve CV outcomes in very high-risk patients. - Sponsored by Amgen (Europe) GmbH.

29 August 2020 (00:00 - 00:00)
Organised by:

ESC 365 is supported by

ESC 365 is supported by